Literature DB >> 22051602

An intravenous stimulus package for oncolytic virotherapy.

Richard Vile1, Alan Melcher.   

Abstract

Mesh：

Year:  2011        PMID： 22051602      PMCID： PMC3222535          DOI： 10.1038/mt.2011.217

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  18 in total

Review 1.  Replication-selective virotherapy for cancer: Biological principles, risk management and future directions.

Authors:  D Kirn; R L Martuza; J Zwiebel
Journal:  Nat Med       Date:  2001-07       Impact factor: 53.440

2.  Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.

Authors:  Caroline J Breitbach; James Burke; Derek Jonker; Joe Stephenson; Andrew R Haas; Laura Q M Chow; Jorge Nieva; Tae-Ho Hwang; Anne Moon; Richard Patt; Adina Pelusio; Fabrice Le Boeuf; Joe Burns; Laura Evgin; Naomi De Silva; Sara Cvancic; Terri Robertson; Ji-Eun Je; Yeon-Sook Lee; Kelley Parato; Jean-Simon Diallo; Aaron Fenster; Manijeh Daneshmand; John C Bell; David H Kirn
Journal:  Nature       Date:  2011-08-31       Impact factor: 49.962

3.  Recent deal highlights hopes for cancer-killing viruses.

Authors:  Jon Evans
Journal:  Nat Med       Date:  2011-03       Impact factor: 53.440

4.  Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy.

Authors:  Timothy Kottke; John Chester; Elizabeth Ilett; Jill Thompson; Rosa Diaz; Matt Coffey; Peter Selby; Gerard Nuovo; Jose Pulido; Debabrata Mukhopadhyay; Hardev Pandha; Kevin Harrington; Alan Melcher; Richard Vile
Journal:  Mol Ther       Date:  2011-07-26       Impact factor: 11.454

Review 5.  Directing systemic oncolytic viral delivery to tumors via carrier cells.

Authors:  Hiroshi Nakashima; Balveen Kaur; E A Chiocca
Journal:  Cytokine Growth Factor Rev       Date:  2010-03-11       Impact factor: 7.638

Review 6.  Striking out at disseminated metastases: the systemic delivery of oncolytic viruses.

Authors:  Kerry Fisher
Journal:  Curr Opin Mol Ther       Date:  2006-08

Review 7.  Oncolytic viruses.

Authors:  E Antonio Chiocca
Journal:  Nat Rev Cancer       Date:  2002-12       Impact factor: 60.716

8.  Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses.

Authors:  Giulia Fulci; Laura Breymann; Davide Gianni; Kazuhiko Kurozomi; Sarah S Rhee; Jianhua Yu; Balveen Kaur; David N Louis; Ralph Weissleder; Michael A Caligiuri; E Antonio Chiocca
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-14       Impact factor: 11.205

9.  Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation.

Authors:  A Vanderplasschen; M Hollinshead; G L Smith
Journal:  J Gen Virol       Date:  1997-08       Impact factor: 3.891

10.  VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.

Authors:  Phonphimon Wongthida; Rosa M Diaz; Feorillo Galivo; Timothy Kottke; Jill Thompson; Alan Melcher; Richard Vile
Journal:  Mol Ther       Date:  2010-10-19       Impact factor: 11.454
View more
  1 in total

1.  Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion.

Authors:  Moanaro Biswas; John B Johnson; Sandeep R P Kumar; Griffith D Parks; Subbiah Elankumarana; Elankumaran Subbiah
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.